利福霉素
生物合成
利福喷丁
利福平
酶
利福昔明
生物化学
化学
结核分枝杆菌
抗生素
生物
肺结核
医学
病理
克拉霉素
潜伏性肺结核
作者
Feifei Qi,Chao Lei,Fengwei Li,Xingwang Zhang,Jin Wang,Wei Zhang,Zhen Fan,Weichao Li,Gong‐Li Tang,Youli Xiao,Guoping Zhao,Shengying Li
标识
DOI:10.1038/s41467-018-04772-x
摘要
Abstract Rifamycin-derived drugs, including rifampin, rifabutin, rifapentine, and rifaximin, have long been used as first-line therapies for the treatment of tuberculosis and other deadly infections. However, the late steps leading to the biosynthesis of the industrially important rifamycin SV and B remain largely unknown. Here, we characterize a network of reactions underlying the biosynthesis of rifamycin SV, S, L, O, and B. The two-subunit transketolase Rif15 and the cytochrome P450 enzyme Rif16 are found to mediate, respectively, a unique C–O bond formation in rifamycin L and an atypical P450 ester-to-ether transformation from rifamycin L to B. Both reactions showcase interesting chemistries for these two widespread and well-studied enzyme families.
科研通智能强力驱动
Strongly Powered by AbleSci AI